with pancytopenia. Our case did not demonstrate any of these features. [4, 5] In both previous cases, the anagen effluvium developed within a month of starting azathioprine at the dose of 50 mg daily, whereas our patient reported to within 48 h. This is slightly atypical and may be explained by the fact that apart from the dose and duration of the anti-mitotic agent, anagen effluvium is also influenced by the synchronization of hair follicle cycling. It has been reported that in conditions with reduced duration of anagen such as androgenetic alopecia, even minor mitotic insult may lead to extensive hair loss. [1] However, our patient had not noticed any hair disorder prior to this. The exact role of the drug in the causation of such rapid hair loss could not be proved in our patient and could have been a mere association.
We believe that in view of the frequent use of azathioprine in different dermatoses, the treating dermatologists should be aware of this rare and distressing adverse effect of azathioprine.
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***** Drug reaction with eosinophilia Drug reaction with eosinophilia and systemic symptoms due to and systemic symptoms due to lercanidipine lercanidipine Sir, Dihydropyridine calcium channel blockers are among the drugs of choice for the treatment of hypertension because of their efficacy and potential beneficial effects. Lercanidipine is a third-generation dihydropyridine calcium channel blocker and is usually well-tolerated. However, dihydropyridine calci um channel blockers can induce adverse skin reactions. A maculopapular rash is the most common manifestation reported. [1] Rarely, systemic reactions have been described. Herein, we report a patient who developed a drug reaction with eosinophilia and systemic symptoms (DRESS) after intake of lercanidipine.
An 81-year-old man with a 12-month-history of hypertension was being treated with delapril and indapamide. Because of poor blood pressure control, he was switched to a regimen of lercanidipine 10 mg once daily. There was no history of drug allergy. The patient denied the use of any other medications. Three weeks later, he developed a febrile skin eruption. Physical examination showed generalized maculopapular exanthema, facial edema with desquamation [ Figure 1 ], cervical lymphadenopathy and oral mucosal involvement. Laboratory investigations revealed leukocytosis (17.6 × 10 9 /L) with eosinophilia (5.1 × 10 9 /L). Creatinine level was 212 μmol/L (normal range: 70-120 μmol/L) and urea nitrogen was 24.17 mmol/L Figure 2 ]. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome was suspected; lercanidipine was stopped and treatment with prednisolone, 20 mg/day orally was started. The patient's condition improved in 4-5 days, the rash cleared, erythema decreased and oral ulceration subsided. He was discharged on a tapering course of prednisolone. After 3 weeks, his laboratory test results returned to normal and his hypertension was stabilized with captopril. A patch test with lercanidipine was requested but the patient refused additional investigations.
Figure 2: Hyperkeratosis, spongiosis and edema in the dermis (H and E, ×100). Inset (lower left); shows lymphocytic infi ltration with numerous eosinophils (arrow) in the upper dermis (H and E, ×400)
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome or drug-induced hypersensitivity syndrome (DHS) is a severe and potentially life-threatening disease presenting with skin rash, eosinophilia and systemic involvement occurring 1-8 weeks after drug introduction. The most frequently implicated drugs are anticonvulsants, sulfonamides, antivirals and allopurinol. The pathophysiological pathways are not fully understood and may be multifactorial involving immunological mechanisms, particularly drug detoxification pathways and sequential reactivation of herpes viruses. [2] Lercanidipine is a dihydropyridine calcium channel blocker indicated for the treatment of mild-to-moderate hypertension. The drug is well tolerated causing much less peripheral edema than amlodipine in most trials. Other lercanidipine-associated adverse events include peripheral flushing, palpitation and dizziness. Cutaneous eruptions related to calcium channel blockers are rare. Maculopapular rash is the most common dermatologic manifestation; however, serious adverse events such as anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis have occasionally been reported. [1] Only a few previous cases of drug reaction with eosinophilia and systemic symptoms syndrome have been reported following exposure to a calcium channel blocker. Diltiazem was the most frequently incriminated calcium channel blocker agent. [3] The onset of the eruption occurred 2-10 days after starting diltiazem. Liver involvement occurred in the majority of the cases. Recently, Moriya et al. presented a case of drug reaction with eosinophilia and systemic symptoms syndrome, which occured 19 months after initiating azelnidipine and verapamil hydrochloride, which appears to be a very long delay in the onset of the syndrome. [4] Our patient's symptoms started 3 weeks after lercanidipine initiation. It was classified as a definitive case of drug reaction with eosinophilia and systemic symptoms according to the RegiSCAR scoring system. [5] According to the Naranjo probability scale, the adverse drug reaction was considered probable. [6] In conclusion, lercanidipine can be added to the list of drugs known to induce drug reaction with eosinophilia and systemic symptoms syndrome.
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